Prothena Corp Public Ltd Co has officially terminated its global license agreement with Bristol Myers Squibb for the PRX019 program. This decision, announced in a recent SEC filing, follows an internal strategic review and signifies a significant shift for the company as it navigates its future in the pharmaceutical sector.

Prothena, known for its work in pharmaceutical preparations, has been active in the development of innovative treatments targeting neurodegenerative diseases. The termination of the agreement means that Prothena will not receive any further milestone payments or royalties related to the PRX019 program. This comes after Bristol Myers Squibb decided not to advance PRX019 further in clinical trials.

Background

Prothena Corp Public Ltd Co, incorporated in Ireland, operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol PRTA. Prothena has been focused on developing therapies for neurodegenerative diseases and has engaged in various partnerships to enhance its research and development capabilities.

In May 2024, Prothena entered into an exclusive global license agreement with Bristol Myers Squibb for PRX019, which was aimed at developing, manufacturing, and commercializing antibody products targeting specific diseases. The agreement included an upfront payment of $80 million and potential future milestones totaling up to $617.5 million.

What the Filing Says

The SEC filing details that Bristol Myers Squibb informed Prothena on October 28, 2026, of its decision not to proceed with the clinical development of PRX019. The filing states, "Following an internal strategic review, Bristol Myers Squibb informed Prothena Corporation plc that it has decided not to advance PRX019 further in the clinic." This decision effectively ends the collaboration on this particular program.

Additionally, the filing notes that Prothena had completed a Phase 1 trial for PRX019, which demonstrated a benign safety profile and met pharmacodynamic targets. However, despite these positive results, Bristol Myers Squibb has opted not to continue with the development.

Impact

This termination may affect Prothena's financial outlook, as it will not receive the anticipated milestone payments or royalties from the PRX019 program. The company had been positioned to benefit significantly from the success of this program, which was part of a broader collaboration with Bristol Myers Squibb initiated in 2018. The loss of this agreement may prompt Prothena to reassess its pipeline and strategic direction moving forward.

In contrast, Bristol Myers Squibb continues to develop moponetug, another antibody program targeting Alzheimer's disease. This program remains active and is currently in a Phase 2 clinical trial, highlighting the ongoing competition in the field of Alzheimer's treatments.

What's Next

The filing does not specify what happens next for Prothena following the termination of the PRX019 Global License Agreement. The company may seek to pivot its focus towards other projects or explore new partnerships to bolster its development pipeline in the competitive pharmaceutical landscape.

For more details, the SEC filing can be accessed under accession number 0001559053-26-000026.